
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.

Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.

Stada Poised To Launch As Calliditas Finally Wins EU Nod For Tarpeyo
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Tarpeyo following delays related to manufacturing questions.

PTC Confident About Commercial Prospects For Gene Therapy Upstaza
PTC CEO Stuart Peltz tells Scrip that cost watchdogs are likely to look favorably on the firm’s transformational gene therapy for a distressing rare brain disorder in children who could not even lift their heads before treatment.

Pipeline Watch: Seven Approvals And 10 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

Homegrown China Oral Antiviral Shows Early Promise
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.

Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.

Ocuphire Chalks Up Another Phase III Success For Nyxol
The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.

Agios CEO Fouse On Building A Sustainable Business Model
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.